Primecap Management Co. CA Sells 58,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Primecap Management Co. CA lessened its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 20.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 232,000 shares of the company's stock after selling 58,000 shares during the quarter. Primecap Management Co. CA owned approximately 0.31% of Nurix Therapeutics worth $4,371,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. US Bancorp DE increased its holdings in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after buying an additional 842 shares during the period. Quarry LP increased its stake in Nurix Therapeutics by 3,746.2% in the third quarter. Quarry LP now owns 2,500 shares of the company's stock valued at $56,000 after acquiring an additional 2,435 shares during the period. Quest Partners LLC lifted its position in shares of Nurix Therapeutics by 21.3% during the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after buying an additional 1,312 shares during the period. Bellevue Group AG acquired a new position in Nurix Therapeutics during the third quarter worth $180,000. Finally, EP Wealth Advisors LLC bought a new position in Nurix Therapeutics during the 3rd quarter valued at about $240,000.

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Houte Hans Van sold 5,825 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $488,660.76. This represents a 14.73 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is owned by corporate insiders.

Remove Ads

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX traded up $0.35 during trading on Monday, reaching $13.34. 976,097 shares of the stock were exchanged, compared to its average volume of 870,816. Nurix Therapeutics, Inc. has a 1-year low of $11.90 and a 1-year high of $29.56. The stock has a fifty day moving average of $17.00 and a two-hundred day moving average of $20.74. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -4.62 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. Sell-side analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Stifel Nicolaus lifted their price target on Nurix Therapeutics from $34.00 to $36.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. BMO Capital Markets began coverage on Nurix Therapeutics in a research note on Friday, December 6th. They issued an "outperform" rating and a $35.00 target price on the stock. Morgan Stanley boosted their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a report on Monday, February 3rd. HC Wainwright increased their target price on Nurix Therapeutics from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Finally, Royal Bank of Canada boosted their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Nurix Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $30.88.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.